Akèy › Kansè pwostat › Texas › Austin
Etid klinik pou Kansè pwostat nan Austin, TX
15 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Austin (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- New Experimental Therapeutics - NEXT Oncology, Austin
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
Ap rekriteFaz 4
- Urology Austin, Austin
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Ap rekrite
- Urology Austin, Austin
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Ap rekriteFaz 1/2
- NEXT Oncology, Austin
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Ap rekriteFaz 3
- Texas Oncology - Central/South Texas ( Site 8003), Austin
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Ap rekriteFaz 3
- Urology Austin, Lakeway · 16 mi lwen
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Ap rekriteFaz 3
- Research Site, Austin
- Research Site, Austin
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Ap rekriteFaz 3
- Urology Austin, PLLC - Research Department, Austin
PSMA PET Combined With MRI for the Detection of PCa
Ap rekriteFaz 3Volontè an sante akeyi
- Urology Austin, Austin
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology Austin, Austin
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology, Austin, TX 78758
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Elligo Health Research, Inc., Austin
Sample Collection for Ongoing Research and Product Evaluation Study
Ap rekriteEtid obsèvasyon
- Natera, Inc., Austin
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 135, Austin
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #4, Austin
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Nashville, TN42 etid
- Seattle, WA42 etid
- Washington, DC38 etid
Lòt etid nan Austin
- Kansè Poumon ki pa ti selil30 etid
- Kansè (tout kalite)20 etid
- Obèsite20 etid
- Kansè Metastatik19 etid
- Kansè kolorektal19 etid
- Ensifizyans kadyak18 etid
- Kansè nan tete18 etid
- Sipwa18 etid
- Kansè ovè17 etid
- Kansè Endomèt15 etid
- Depresyon14 etid
- Kansè tete negatif triple13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.